Clinical Trial Update: The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial evaluating tolvaptan to prevent renal dysfunction in high-risk heart failure patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: University of Michigan | Conditions: Heart Failure | Phase 4 | Status: WITHDRAWN